-
Adv Sci: Reveals the important role of TGF beta 2 in esophageal cancer metastasis and targeted intervention strategies.
Time of Update: 2020-08-04
Tumor metastasis is one of the top ten characteristics of cancer, and more than 90% of cancer deaths are closely related to tumor metastasis. More and more studies point out that the tumor microenvir
-
European J. Meany: Eat oranges later and turn off the lights! Studies have shown that too much citrus intake increases the risk of skin cancer.
Time of Update: 2020-08-04
, on July 24th researchers from the University of Saclay, France, released the results of a European Cancer and Nutrition Prospective Survey (EPIC), which involved 520,000 participants and looked at the potential link between citrus intake and skin cancer risk.
-
Sci Adv: Identify the new "oxidative stress sensor" MTK1.
Time of Update: 2020-08-04
MTK1 SAPKKK is considered to be a new type of human oxidative stress sensor that senses excess reactive oxygen in the body and transmits that information to cells, leading to cell death and the production of inflammatory cytokines.
-
Nat Rev Cancer: Immune cell metabolism in cancer.
Time of Update: 2020-08-04
inhibits the metabolic processes of immune populations and cancer cells can directly target metabolic pathways that reduce activity, as well as inactivation to consume nutrients (e.g. ARG1, IDO), resulting in toxic metabolites (e.g. lactic acid and CD73) or the number of effective cells that induce metabolic control (e.g. R-2-HG's mutant 1 subgeneration).
-
Int J Clin Oncol: PembrolizumabVS chemotherapy treatment for recurrent advanced urethra cancer.
Time of Update: 2020-08-04
Open-labeled, randomized, active-controlled KEYNOTE-045 study (NCT02256436) showed that the second-line pembrolizumab significantly improved the total survival (OS) of patients with advanced/metastatic urethra cancer (UC) patients with first-line platinum-containing chemotherapy compared to standard chemotherapy (eucalyptus alcohol, doselataly, or acefluorone).
pembrolizumab and chemotherapy PFS were 2.0 and 4.9 months respectively (HR 1.71, 95% CI 0.95-3.08).
-
Under the era of immuno-targeted treatment of lung cancer, the status of radiotherapy cornerstone is difficult to shake, and precision radiotherapy is becoming more and more important.
Time of Update: 2020-08-04
and for extensive brain metastasis and meninges transfer, radiation therapy also plays a major therapeutic role, for driving gene-positive patients, radiotherapy combined targeted therapy can further improve local control and survival rate, increase clinical benefits.
-
PNAS: The University of California is developing a new method of targeting cancer with "synthetic lethal effects."
Time of Update: 2020-08-04
in a paper published online July 27, 2020 in the Proceedings of the National Academy of Sciences (PNAS), "FEN1 endonuclease as a therapeutic target for human cancer with defects in homologous resle", researchers at the San Diego Division of the Ludwig Institute of Cancer and the University of California, San Diego School of Medicine, found that inhibiting a key enzyme that could cause two major types of breast and ovarian cancer death sey ness in mice.
-
Nat Commun: The Sipeng team achieved long-range observation of live cell mitochondrial STED.
Time of Update: 2020-08-04
the work developed a new mitochondrial dye MitoESq-635, which is 3.4 times less saturated than the traditional ATTO 647N, which is conducive to long-term STED hyper-resolution imaging.
-
CAR-T cell therapy Idecabagene Vicleucel for relapsed refractive multiple myeloma: submitted to BLA.
Time of Update: 2020-08-04
however, there are many treatments that can be used to treat multiple myeloma.
Critical II KarMMa study evaluated the effectiveness and safety of patients who had been exposed to immunomodulators (IMiD), protease inhibitors (Pi), and recurrent, refractory multiple myeloma with anti-CD38 antibodies.
-
Radiother Oncol: cytoximatoxamcine-RT combined avic monotorthescans can be used to treat patients with advanced HNSCC who are not suitable for cisplatin treatment.
Time of Update: 2020-08-04
phase-I feasibility test for patients with advanced HNSCC who are not suitable for cisplatin treatment (simultaneously maintained at 10mg/kg Q2W plus 4 months) phase-I feasibility test (plan n, NCT02938273).
in general, sitoxioxion-RT Gaaveit is feasible for patients with advanced HNSCC who are not suitable for cisplatin treatment.
-
Cell Res: World premiere! Fudan University has released a three-negative breast cancer precision treatment plan, so that patients from the mountains to the water to the willow dark flowering.
Time of Update: 2020-08-04
According to the 2018 International Agency for Research on Cancer (IARC) survey, breast cancer has a global incidence of 24.2 percent of female cancers, the highest rate among women, with 52.9 percent
-
Nature: The gut environment "gives" two sides to the p53 gene: anti-cancer or cancer-promoting.
Time of Update: 2020-08-04
However, if the gut microbiome produces certain high levels of metabolites, such as some found in antioxidant-rich foods such as black tea and hot cocoa, it becomes a hotbed of mutant genes and accelerates the growth of bowel cancer.
-
Am J Clin Oncol: Meth-ctDNA or potential prognosis marker for advanced rectal cancer.
Time of Update: 2020-08-04
a prospective collection of serum samples in a Phase III trial for localized late-stage rectal cancer.
compared the total survival (OS) of meth-ctDNA-positive and negative patients with the distant metastasis rate; investigates the importance of quantitative load by considering the component abundance of meth-ct DNA relative to total circulating DNA.
-
Professor Shen Lin: CSCO gastrointestinal mesoma diagnosis guidelines issued, based on genotype recommended treatment options.
Time of Update: 2020-08-04
it is worth noting that this edition of the CSCO Gastroenteromelioma Diagnosis And Treatment Guidelines, based on the follow-up drug recommendations based on the number of treatment lines, recommendpatients with first-line treatment according to the genotyt sub-section, choose more accurate targeted treatment: if carrying PDGFRA exon 18 mutation, especially D842V mutation patients, recommended apostinib treatment.
-
Sci Adv: Cancer cells grow "fingers" in order to transfer! The leading cell "fingers" of highly invasive lung cancer are longer.
Time of Update: 2020-08-04
recently, a team of researchers found that a tiny "finger"-like protrusion called a silky pseudo-foot drives aggressive behavior in lung cancer cells, and leading cells have longer "fingers" than follow-up cells.
-
Clin cancer res: Endometrial-like ovarian cancer or a treatment strategy for endometrial cancer may be used.
Time of Update: 2020-08-04
511 ENOC tumors were divided into four EC-induced molecular subtypes through immunohistization and mutant biomarkers: low-risk POLE mutant (POLEmut), medium-risk mismatch repair defect type (MMRd), high-risk p53 abnormality (p53abn) and medium risk (NSMP) without special molecules.
-
Oral Dis: Improved efficacy and safety in Patients with Dosithalaplus cisplatin and 5-fluorourea (TPF) in SCCHN patients in China.
Time of Update: 2020-08-04
The purpose of this study was to assess the efficacy and safety of dose-improved Doxixace platinum and 5-fluorourea (TPF) in patients with head and neck squamous cell carcinoma (SCCHN) in China.
in the TPF and PF groups, 104 (94.5%) and 110 (93.2%) patients had a treatment emergency.
-
New Assisted Immunotherapy: Concepts and the Future in Non-Small Cell Lung Cancer.
Time of Update: 2020-08-01
the main endpoint of the trial is significant pathological remission, in addition to the researchers also removed the tumor's genetic mutation, the patient's T-cell changes in the body, after all, the new immunotherapy has many unsolved mysteries, can get more data must be better.
-
PROFESSOR ASCO 2020 CHEN JIE: EVEN IF SMALL, EFFORTS NEED TO BE MADE TO MOVE FORWARD, ASCO ON THE NETS-RELATED RESEARCH.
Time of Update: 2020-07-31
. . Professor Chen Jie: at the ASCO this year, there are several abstracts on NETs that deserve attention, including an epidemiological summary, two molecular marker abstracts, two summaries of
-
The world's first BCMA targeted therapy! GlaxoSmithKline Blenrep (belantamab mafodotin) is about to be approved for listing in the US and Europe!
Time of Update: 2020-07-31
!--webeditor: "page title" - / GSK recently announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued an active review of the approval of Blenrep (be
